Treatment of refractory pulmonary arterial hypertension with inhaled epoprostenol in an infant with congenital heart disease

Joshua Kovach, Laura Ibsen, Michael Womack, David Steusse, Yuk M. Law

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Epoprostenol is a potent arterial vasodilator, and its administration by inhalation localizes its effects to the pulmonary circulation. In this case report, we describe a 3-month-old male patient with significant refractory pulmonary hypertension after pulmonary artery banding and placement of a Blalock-Taussig shunt. This patient continued to have significant hypoxic episodes despite maximal therapy with sedation, alkalinization, sildenafil, and inhaled nitric oxide. After the addition of inhaled epoprostenol, improvements in both clinical response and echocardiography-based hemodynamics were observed. The case supports a synergistic role among the agents in the treatment of pulmonary arterial hypertension from congenital heart disease.

Original languageEnglish (US)
Pages (from-to)194-198
Number of pages5
JournalCongenital Heart Disease
Volume2
Issue number3
DOIs
StatePublished - May 2007

Fingerprint

Epoprostenol
Pulmonary Hypertension
Heart Diseases
Inhalation Administration
Blalock-Taussig Procedure
Pulmonary Circulation
Vasodilator Agents
Pulmonary Artery
Echocardiography
Nitric Oxide
Hemodynamics
Therapeutics
Sildenafil Citrate

Keywords

  • Congenital heart disease
  • Epoprostenol
  • Pulmonary arterial hypertension
  • Pulmonary vasodilators

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health
  • Surgery
  • Radiology Nuclear Medicine and imaging

Cite this

Treatment of refractory pulmonary arterial hypertension with inhaled epoprostenol in an infant with congenital heart disease. / Kovach, Joshua; Ibsen, Laura; Womack, Michael; Steusse, David; Law, Yuk M.

In: Congenital Heart Disease, Vol. 2, No. 3, 05.2007, p. 194-198.

Research output: Contribution to journalArticle

@article{47eb568fe2fd4ddfb3490439e0adf10e,
title = "Treatment of refractory pulmonary arterial hypertension with inhaled epoprostenol in an infant with congenital heart disease",
abstract = "Epoprostenol is a potent arterial vasodilator, and its administration by inhalation localizes its effects to the pulmonary circulation. In this case report, we describe a 3-month-old male patient with significant refractory pulmonary hypertension after pulmonary artery banding and placement of a Blalock-Taussig shunt. This patient continued to have significant hypoxic episodes despite maximal therapy with sedation, alkalinization, sildenafil, and inhaled nitric oxide. After the addition of inhaled epoprostenol, improvements in both clinical response and echocardiography-based hemodynamics were observed. The case supports a synergistic role among the agents in the treatment of pulmonary arterial hypertension from congenital heart disease.",
keywords = "Congenital heart disease, Epoprostenol, Pulmonary arterial hypertension, Pulmonary vasodilators",
author = "Joshua Kovach and Laura Ibsen and Michael Womack and David Steusse and Law, {Yuk M.}",
year = "2007",
month = "5",
doi = "10.1111/j.1747-0803.2007.00097.x",
language = "English (US)",
volume = "2",
pages = "194--198",
journal = "Congenital Heart Disease",
issn = "1747-079X",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Treatment of refractory pulmonary arterial hypertension with inhaled epoprostenol in an infant with congenital heart disease

AU - Kovach, Joshua

AU - Ibsen, Laura

AU - Womack, Michael

AU - Steusse, David

AU - Law, Yuk M.

PY - 2007/5

Y1 - 2007/5

N2 - Epoprostenol is a potent arterial vasodilator, and its administration by inhalation localizes its effects to the pulmonary circulation. In this case report, we describe a 3-month-old male patient with significant refractory pulmonary hypertension after pulmonary artery banding and placement of a Blalock-Taussig shunt. This patient continued to have significant hypoxic episodes despite maximal therapy with sedation, alkalinization, sildenafil, and inhaled nitric oxide. After the addition of inhaled epoprostenol, improvements in both clinical response and echocardiography-based hemodynamics were observed. The case supports a synergistic role among the agents in the treatment of pulmonary arterial hypertension from congenital heart disease.

AB - Epoprostenol is a potent arterial vasodilator, and its administration by inhalation localizes its effects to the pulmonary circulation. In this case report, we describe a 3-month-old male patient with significant refractory pulmonary hypertension after pulmonary artery banding and placement of a Blalock-Taussig shunt. This patient continued to have significant hypoxic episodes despite maximal therapy with sedation, alkalinization, sildenafil, and inhaled nitric oxide. After the addition of inhaled epoprostenol, improvements in both clinical response and echocardiography-based hemodynamics were observed. The case supports a synergistic role among the agents in the treatment of pulmonary arterial hypertension from congenital heart disease.

KW - Congenital heart disease

KW - Epoprostenol

KW - Pulmonary arterial hypertension

KW - Pulmonary vasodilators

UR - http://www.scopus.com/inward/record.url?scp=34250171137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250171137&partnerID=8YFLogxK

U2 - 10.1111/j.1747-0803.2007.00097.x

DO - 10.1111/j.1747-0803.2007.00097.x

M3 - Article

C2 - 18377465

AN - SCOPUS:34250171137

VL - 2

SP - 194

EP - 198

JO - Congenital Heart Disease

JF - Congenital Heart Disease

SN - 1747-079X

IS - 3

ER -